Addex Therapeutics Ltd. (ADXN) stock
ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on May 15, 2026Score 0/30
$3.06−0.44 (-12.57%)
Close on Nov 18, 2026Market cap $62.83KP/E –Yield –
Addex Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was CHF 671.65K, down 21.4% from the year before. The highest annual figure on record is CHF 12.84M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | CHF 671.65K | -21.4% |
| FY2024 | Dec 31, 2024 | CHF 854.31K | -28.0% |
| FY2023 | Dec 31, 2023 | CHF 1.19M | -85.6% |
| FY2022 | Dec 31, 2022 | CHF 8.24M | -35.8% |
| FY2021 | Dec 31, 2021 | CHF 12.84M | +23.8% |
| FY2020 | Dec 31, 2020 | CHF 10.37M | -16.7% |
| FY2019 | Dec 31, 2019 | CHF 12.45M | +153.2% |
| FY2018 | Dec 31, 2018 | CHF 4.92M | +87.1% |
| FY2017 | Dec 31, 2017 | CHF 2.63M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | CHF 37.99K | -99.3% |
| Q2 FY2025 | Jun 30, 2025 | CHF 234.45K | -93.7% |
| Q2 FY2024 | Jun 30, 2024 | CHF 339.32K | – |
| Q2 FY2023 | Jun 30, 2023 | CHF 1.88M | – |
| Q2 FY2022 | Jun 30, 2022 | CHF 5.75M | – |
| Q2 FY2021 | Jun 30, 2021 | CHF 3.73M | – |
See a number that looks wrong?